EU review for Regeneron/Sanofi’s RA biologic
European regulators have agreed to review Regeneron and Sanofi’s application to market the biologic sarilumab as a treatment for rheumatoid arthritis.
Read More
Tag: SARIL-RA
- Myomaker Bio unveils lab‑grown human muscle platform to transform drug testing
- Survodutide delivers 16.6% weight loss in major phase 3 obesity trial
- Kahimmune Therapeutics signs collaboration agreement with Gustave Roussy
- BioDuro and CTI Biotechnology form partnership to accelerate preclinical drug development
- Asgard Therapeutics to present new preclinical data on AT‑108 at ASGCT 2026
